Table 2.

Table of combined melanoma targeted therapies in progress.

Clinical trial number	Description
NCT01512251	BKM120 (PI3K inhibitor) + vemurafenib in BRAF V600E/K advanced melanoma
NCT01616199	PX866 (PI3K inhibitor) + vemurafenib in advanced melanoma
NCT01363232	Safety and pharmacodynamics of BKM120 (PI3K inhibitor) + MEK162 (MEK1/2 inhibitor) in advanced solid tumors
NCT01673737	Phase I/Ib trial of SAR260301 (PI3K inhibitor) +/− vemurafenib in advanced cancers
NCT01820364	LGX818 (RAF inhibitor) + MEK162, BKM120, LEE011, BGJ398, or INC280 in advanced BRAF melanoma
NCT02065063	Safety, anti-cancer activity, and pharmacodynamics of trametinib + palbociclib (CDK4/6 inibitor) in solid tumors
NCT01777776	Safety and efficacy of LEE011 (CDK4/6 inhibitor) + LGX818 (RAF inhibitor) in BRAF melanoma
NCT01826448	Phase1b trial of PLX3397 (Kit inhibitor) + vemurafenib in BRAF melanoma
NCT01928940	Japanese Phase I/II trial of GSK2118436 (dabrafenib) + GSK1120212 (trametinib) in BRAF solid tumors and cutaneous melanoma
NCT01433991	E7050 (cMET + VEGF inhibitor) + E7080 (VEGF inhibitor) in glioblastoma or advanced melanoma
NCT01909453	LGX818 (RAF inhibitor) +/− MEK162 (MEK1/2 inhibitor) vs vemurafenib in BRAF melanoma
NCT01701037	Dabrafenib +/− trametinib before surgery in advanced melanoma that can be removed surgically
NCT01562899	MEK162 (MEK1/2 inhibitor) + AMG479 (IGFR-1 mAb) in solid tumors
NCT01519427	Selumetinib (MEK inhibitor) + MK2206 (AKT inhibitor) in advanced melanoma that failed vemurafenib or dabrafenib
NCT01271803	Vemurafenib + GDC0973 (MEK inhibitor) in BRAF advanced melanoma
NCT01380818	MEK inhibitor + PI3K/mTOR inhibitor in advanced solid tumors
NCT01781572	Phase Ib/II trial of LEE011 (CDK4/6 inhibitor) + MEK162 (MEK1/2 inhibitor) in NRAS melanoma